← Leaderboards
Jean-Pierre J Issa
University Of Texas Md Anderson Can Ctr
$21,637,643
Attributed
$24,824,130
Total exposure
25
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$67,549,286 · 29
By mechanism
P50$38,535,944 · 15
U54$13,698,150 · 3
R01$12,650,102 · 7
P01$1,768,612 · 2
R33$747,422 · 1
P30$149,056 · 1
Top collaborators
- Joel Erblich13 shared
- Grace X Ma12 shared
- Olorunseun O Ogunwobi12 shared
- Stephen B Baylin5 shared
- Christian Jobin5 shared
- Peter A Jones5 shared
- Hui-Lin Pan5 shared
- Marina Y Konopleva2 shared
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- Lorenzo Cohen$18,186,221
- Douglas D. Boyd$4,994,999
- Bogdan A Czerniak$13,889,235
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsProgramsEpigenetic ProcessClinical TrialsResearch PersonnelDna MethylationResearch Project GrantsGene ExpressionCollaborationsFundingDesignTumorTranslational ResearchCancer TherapyLeukemiaCpg IslandsScientistBasePharmaceutical PreparationsCareerGenesResponseEpigenetic TherapyInnovation
Grant awards (122)
Epigenetic Therapies - New Approaches$2,521,916
P50 · FY2025 · CA · contact PI
Cyclin Dependent Kinases as Epigenetic Therapy Targets$535,736
P50 · FY2025 · CA · contact PI
Admin Core$430,269
P50 · FY2025 · CA · contact PI
Genomics Core$248,500
P50 · FY2025 · CA · contact PI
Career Enhancement Program$88,750
P50 · FY2025 · CA · contact PI
Developmental Research Program$88,750
P50 · FY2025 · CA · contact PI
Epigenetic Therapies - New Approaches$2,421,039
P50 · FY2024 · CA · contact PI
Cyclin Dependent Kinases as Epigenetic Therapy Targets$514,307
P50 · FY2024 · CA · contact PI
Admin Core$413,060
P50 · FY2024 · CA · contact PI
Career Enhancement Program$85,197
P50 · FY2024 · CA · contact PI
Developmental Research Program$85,197
P50 · FY2024 · CA · contact PI
Epigenetic Therapies - New Approaches$2,345,381
P50 · FY2023 · CA · contact PI
Cyclin Dependent Kinases as Epigenetic Therapy Targets$498,235
P50 · FY2023 · CA · contact PI
Admin Core$400,151
P50 · FY2023 · CA · contact PI
Elucidating the Roles of Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease among Asian American Patients with Chronic Hepatitis B$189,986
U54 · FY2023 · CA
Career Enhancement Program$82,536
P50 · FY2023 · CA · contact PI
Developmental Research Program$82,536
P50 · FY2023 · CA · contact PI
Epigenetic Therapies - New Approaches$2,345,381
P50 · FY2022 · CA · contact PI
1/2 TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership$1,591,989
U54 · FY2022 · CA
(2/2) TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership$1,015,126
U54 · FY2022 · CA
Role of the microbiota in DNA methylation and CRC development$570,926
R01 · FY2022 · CA · contact PI
Cyclin Dependent Kinases as Epigenetic Therapy Targets$498,233
P50 · FY2022 · CA · contact PI
Admin Core$400,152
P50 · FY2022 · CA · contact PI
Project 1: New epigenetic therapy targets$269,821
P50 · FY2022 · CA · contact PI
(2/2) TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership$127,803
U54 · FY2022 · CA
Career Enhancement Program$82,536
P50 · FY2022 · CA · contact PI
Developmental Research Program$82,536
P50 · FY2022 · CA · contact PI
Epigenetic Therapies - New Approaches$2,269,729
P50 · FY2021 · CA · contact PI
1/2 TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership$1,624,631
U54 · FY2021 · CA
(2/2) TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership$1,008,742
U54 · FY2021 · CA
Role of the microbiota in DNA methylation and CRC development$564,123
R01 · FY2021 · CA · contact PI
Cyclin Dependent Kinases as Epigenetic Therapy Targets$482,163
P50 · FY2021 · CA · contact PI
Admin Core$387,243
P50 · FY2021 · CA · contact PI
Project 1: New epigenetic therapy targets$269,820
P50 · FY2021 · CA · contact PI
(2/2) TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership$130,428
U54 · FY2021 · CA
Career Enhancement Program$79,875
P50 · FY2021 · CA · contact PI
Developmental Research Program$79,875
P50 · FY2021 · CA · contact PI
1/2 TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership$1,657,271
U54 · FY2020 · CA
(2/2) TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership$895,790
U54 · FY2020 · CA
Role of the microbiota in DNA methylation and CRC development$600,157
R01 · FY2020 · CA · contact PI
Project 1: New epigenetic therapy targets$339,301
P50 · FY2020 · CA · contact PI
SPORE University of Texas M. D. Anderson Cancer Center-Leukemia$1,708,776
P50 · FY2019 · CA
1/2 TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership$1,608,811
U54 · FY2019 · CA
(2/2) TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership$1,008,081
U54 · FY2019 · CA
Role of the microbiota in DNA methylation and CRC development$602,612
R01 · FY2019 · CA · contact PI
Project 1: New epigenetic therapy targets$269,820
P50 · FY2019 · CA · contact PI
1/2 TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership$1,671,024
U54 · FY2018 · CA
SPORE University of Texas M. D. Anderson Cancer Center-Leukemia$1,392,864
P50 · FY2018 · CA
(2/2) TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership$1,050,067
U54 · FY2018 · CA
Role of the microbiota in DNA methylation and CRC development$567,545
R01 · FY2018 · CA · contact PI
Project 1: New epigenetic therapy targets$250,447
P50 · FY2018 · CA · contact PI
Epigenetic Factors and the Microbiome in Disparities in Colon Cancer Outcomes$118,401
U54 · FY2018 · CA · contact PI
Cancer Epigenetics Program (03)$37,782
P30 · FY2018 · CA · contact PI
Cancer Epigenetics Program (03)$10,869
P30 · FY2018 · CA · contact PI
Cancer Epigenetics Program (03)$5,966
P30 · FY2018 · CA · contact PI
Cancer Epigenetics Program (03)$43,445
P30 · FY2017 · CA · contact PI
Regulators of Cancer-Specific DNA Hypermethylation.$317,475
R01 · FY2016 · CA · contact PI
Cancer Epigenetics Program (03)$50,994
P30 · FY2016 · CA · contact PI
Epigenetic Mechanisms of Neuropathic Pain$694,547
R01 · FY2015 · DE
Regulators of Cancer-Specific DNA Hypermethylation.$317,475
R01 · FY2015 · CA · contact PI
Epigenetic Mechanisms of Neuropathic Pain$696,785
R01 · FY2014 · DE
Regulators of Cancer-Specific DNA Hypermethylation.$307,951
R01 · FY2014 · CA · contact PI
The CML Epigenome - Implications for Therapy$200,021
P01 · FY2014 · CA · contact PI
Epigenetic Mechanisms of Neuropathic Pain$671,107
R01 · FY2013 · DE
Regulators of Cancer-Specific DNA Hypermethylation.$299,720
R01 · FY2013 · CA · contact PI
The CML Epigenome - Implications for Therapy$297,843
P01 · FY2013 · CA · contact PI
Epigenetic Mechanisms of Neuropathic Pain$701,398
R01 · FY2012 · DE
Regulators of Cancer-Specific DNA Hypermethylation.$332,101
R01 · FY2012 · CA · contact PI
Epigenetics and Epigenetic Therapy in AML$217,094
P50 · FY2012 · CA · contact PI
The CML Epigenome - Implications for Therapy$208,260
P01 · FY2012 · CA · contact PI
Developmental Research Program$74,474
P50 · FY2012 · CA · contact PI
Administrative Core$73,423
P50 · FY2012 · CA · contact PI
Epigenetic Mechanisms of Neuropathic Pain$703,775
R01 · FY2011 · DE
Randomized study of combined epigenetic therapy$281,979
R01 · FY2011 · CA · contact PI
Epigenetics and Epigenetic Therapy in AML$265,746
P50 · FY2011 · CA · contact PI
The CML Epigenome - Implications for Therapy$205,105
P01 · FY2011 · CA · contact PI
Developmental Research Program$128,179
P50 · FY2011 · CA · contact PI
Administrative Core$127,182
P50 · FY2011 · CA · contact PI
Randomized study of combined epigenetic therapy$1,843
R01 · FY2011 · CA · contact PI
University of Texas M.D. Anderson Cancer Center SPORE - Leukemia$2,158,273
P50 · FY2010 · CA · contact PI
Randomized study of combined epigenetic therapy$292,600
R01 · FY2010 · CA · contact PI
Epigenetics and Epigenetic Therapy in AML$264,184
P50 · FY2010 · CA · contact PI
The CML Epigenome - Implications for Therapy$214,538
P01 · FY2010 · CA · contact PI
Developmental Research Program$126,197
P50 · FY2010 · CA · contact PI
Administrative Core$125,218
P50 · FY2010 · CA · contact PI
University of Texas M.D. Anderson Cancer Center SPORE - Leukemia$2,300,000
P50 · FY2009 · CA · contact PI
Randomized study of combined epigenetic therapy$292,600
R01 · FY2009 · CA · contact PI
Epigenetics and Epigenetic Therapy in AML$289,886
P50 · FY2009 · CA · contact PI
Epigenetics of MDS$206,306
P01 · FY2009 · CA · contact PI
Developmental Research Program$137,114
P50 · FY2009 · CA · contact PI
Administrative Core$136,049
P50 · FY2009 · CA · contact PI
University of Texas M.D. Anderson Cancer Center SPORE - Leukemia$52,857
P50 · FY2009 · CA · contact PI
University of Texas M.D. Anderson Cancer Center SPORE - Leukemia$2,300,000
P50 · FY2008 · CA · contact PI
Randomized study of combined epigenetic therapy$292,600
R01 · FY2008 · CA · contact PI
DNA Methylation in Colon Cancer Metastasis$264,158
R01 · FY2008 · CA · contact PI
Epigenetics and Epigenetic Therapy in AML$196,181
P50 · FY2008 · CA · contact PI
Epigenetics of MDS$149,400
P01 · FY2008 · CA · contact PI
Developmental Research Program$92,643
P50 · FY2008 · CA · contact PI
Administrative Core$91,921
P50 · FY2008 · CA · contact PI
University of Texas M.D. Anderson Cancer Center SPORE - Leukemia$40,163
P50 · FY2008 · CA · contact PI
University of Texas M.D. Anderson Cancer SPORE-Leukemia$2,363,102
P50 · FY2007 · CA · contact PI
Randomized study of combined epigenetic therapy$292,600
R01 · FY2007 · CA · contact PI
DNA Methylation in Colon Cancer Metastasis$264,158
R01 · FY2007 · CA · contact PI
Diet and DNA methylation in colon mucosa and adenomas$256,111
R01 · FY2007 · CA · contact PI
Epigenetics of MDS$145,578
P01 · FY2007 · CA · contact PI
University of Texas M.D. Anderson Cancer SPORE-Leukemia$2,433,679
P50 · FY2006 · CA · contact PI
DNA Methylation in Colon Cancer Metastasis$272,048
R01 · FY2006 · CA · contact PI
Diet and DNA methylation in colon mucosa and adenomas$266,998
R01 · FY2006 · CA · contact PI
Epigenetics of MDS$141,561
P01 · FY2006 · CA · contact PI
DNA Methylation in Colon Cancer Metastasis$74,955
R01 · FY2006 · CA · contact PI
University of Texas M.D. Anderson Cancer SPORE-Leukemia$2,492,247
P50 · FY2005 · CA
DNA Methylation in Colon Cancer Metastasis$278,595
R01 · FY2005 · CA
Diet and DNA methylation in colon mucosa and adenomas$269,816
R01 · FY2005 · CA
Epigenetics of MDS$0
P01 · FY2005 · CA
Diet and DNA methylation in colon mucosa and adenomas$287,021
R01 · FY2004 · CA
DNA Methylation in Colon Cancer Metastasis$278,595
R01 · FY2004 · CA
Neoplasia and Methylated CpG Islands Amplification$256,542
R33 · FY2004 · CA
Neoplasia and Methylated CpG Islands Amplification$249,068
R33 · FY2003 · CA
METHYLATION PROFILING IN COLORECTAL CANCER$245,103
R01 · FY2003 · CA
METHYLATION PROFILING IN COLORECTAL CANCER$245,245
R01 · FY2002 · CA
Neoplasia and Methylated CpG Islands Amplification$241,812
R33 · FY2002 · CA
METHYLATION PROFILING IN COLORECTAL CANCER$245,380
R01 · FY2001 · CA